Literature DB >> 19629070

Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Jeffrey A Engelman1.   

Abstract

There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19629070     DOI： 10.1038/nrc2664

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  157 in total

1.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

2.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Authors:  Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

4.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

Review 5.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

6.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Authors:  Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

7.  Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Authors:  Jennifer Dunlap; Claudia Le; Arielle Shukla; Janice Patterson; Ajia Presnell; Michael C Heinrich; Christopher L Corless; Megan L Troxell
Journal:  Breast Cancer Res Treat       Date:  2009-05-06       Impact factor: 4.872

8.  Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.

Authors:  Charles T Miller; Justin R Moy; Lin Lin; Matthew Schipper; Daniel Normolle; Dean E Brenner; Mark D Iannettoni; Mark B Orringer; David G Beer
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

9.  PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects.

Authors:  Enrico Patrucco; Antonella Notte; Laura Barberis; Giulio Selvetella; Angelo Maffei; Mara Brancaccio; Stefano Marengo; Giovanni Russo; Ornella Azzolino; Sergei D Rybalkin; Lorenzo Silengo; Fiorella Altruda; Reinhard Wetzker; Matthias P Wymann; Giuseppe Lembo; Emilio Hirsch
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640
View more
  997 in total

Review 1.  Utility of mTOR inhibition in hematologic malignancies.

Authors:  Anas Younes; Nousheen Samad
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 3.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

4.  Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Authors:  Dimitra Bourboulia; Sandra Jensen-Taubman; Matthew R Rittler; Hui Ying Han; Tania Chatterjee; Beiyang Wei; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

5.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors:  Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

6.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

7.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

8.  [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2.

Authors:  Myoung Ok Kim; Mee-Hyun Lee; Naomi Oi; Sung-Hyun Kim; Ki Beom Bae; Zunnan Huang; Dong Joon Kim; Kanamata Reddy; Sung-Young Lee; Si Jun Park; Jae Young Kim; Hua Xie; Joydeb Kumar Kundu; Zae Young Ryoo; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

9.  A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.

Authors:  Rolando Perez-Lorenzo; Kamraan Z Gill; Che-Hung Shen; Feng X Zhao; Bin Zheng; Hans-Joachim Schulze; David N Silvers; Georg Brunner; Basil A Horst
Journal:  J Invest Dermatol       Date:  2013-11-28       Impact factor: 8.551

Review 10.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.